2 completed. 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Completed 2 |
Follow Stefan Heber: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mechanisms of Pain Hypersensitivity in a Human Skin Inflammation Model Synthetic interstitial fluid (SIF) / SIF neutral pH, Synthetic interstitial fluid (SIF) / SIF acidic pH, Synthetic interstitial fluid (SIF) / SIF acidic pH + BCTC 1 µM - Pain | Early Phase 1 | Completed | Stefan Heber | 42 | 2025-06-17 | 2025-07-29 |
| Peripheral KV7 Activation for Pain Relief Capsaicin only (7.6 ng), Capsaicin + Flupirtine 0.5 µg, Capsaicin + Flupirtine 1.2 µg - Pain | Early Phase 1 | Completed | Stefan Heber | 32 | 2025-05-08 | 2025-06-10 |
Pain (2) · Hyperalgesia (1) · Inflammation (1)
Capsaicin (1) · Lipopolysaccharides (1) · azeliragon (1) · ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate (1) · flupirtine (1)
Austria (2)
PMID 10191237, PMID 18299127, PMID 20562702, PMID 21270403, PMID 28062311, PMID 30782041, PMID 32107360, PMID 33548580, PMID 33863932, PMID 34293819, PMID 34935141, PMID 42830319, PMID 5781321